Respiratory And Thoracic Cancers
Results showed that progression-free survival (PFS), the primary endpoint, was significantly longer in Tagrisso-treated patients vs EGFR tyrosine kinase inhibitor-treated patients (18.9 months vs 10.2 months; hazard ratio [HR] 0.46, 95% CI: 0.37, 0.57; P <.0001).
The researchers identified 168 prescriptions associated with HNCA and 571 with LCCA diagnoses. Compared to patients with LCCA, patients with HNCA had significantly increased odds of being prescribed an opioid (odds ratio, 1.68).
Compared with hot tea drinking alone, hot tea drinking combined with either alcohol consumption or smoking was associated with increased risk for esophageal cancer.
"These results indicate that nicotine nitrosation occurs in vivo in mice and that e-cigarette smoke is carcinogenic to the murine lung and bladder and harmful to the murine heart," the authors write.
To determine if a patient is eligible for Gilotrif, physicians must conduct biomarker testing to determine the type of EGFR mutation present.
In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer screening efficiency.
Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial
Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC).
The researchers found that over four years, 299 patients developed a basal cell carcinoma end point and 108 developed a squamous cell carcinoma end point.
The approval was based on the Phase 3 ALEX study which evaluated the safety and efficacy of Alecensa versus crizotinib in patients with ALK-positive NSCLC who had not received prior systemic therapy for metastatic disease and whose tumors were characterized as ALK-positive by the VENTANA ALK CDx Assay.
The FDA granted accelerated approval of Alunbrig, a kinase inhibitor, for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.
A significantly higher response rate was seen with durvalumab versus placebo (28.4 versus 16.0%), with a longer median duration of response (72.8 versus 46.8% of patients had ongoing response at 18 months).
Upon evaluation of the 10-year average supplement dose, it was found that lung cancer risk increased almost 2-fold in men taking >20mg/day of vitamin B6 (HR: 1.82; 95% CI: 1.25, 2.65) and >55mg/day of vitamin B12 (HR: 1.98; 95% CI: 1.32, 2.97) versus nonusers.
Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).
In March 2016, tesevatinib was designated Orphan Drug status for the treatment of autosomal recessive polycystic kidney disease (ARPKD).
Imfinzi, an anti-PD-L1 monoclonal antibody, was previously granted accelerated approval from the FDA for locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
The approval for Tafinlar and Mekinist combination therapy was based on a Phase 2 international, multicenter, 3-cohort, non-randomized, non-comparative, open-label trial (Study BRF113928) in patients with locally confirmed stage IV NSCLC with BRAF V600E mutation.
The researchers found that the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy among the 423 patients with a PD-L1 expression level of 5% or more.
The second clinical trial compared dacomitinib to the current standard targeted drug gefitinib in treating epidermal growth factor receptor-positive NSCLC.